<scp>TIM</scp>‐4 increases the proportion of <scp>CD4</scp><sup>+</sup><scp>CD25</scp><sup>+</sup><scp>FOXP3</scp><sup>+</sup> regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting <scp>IL</scp>‐6 secretion
TIM-4 has the potential to be an immunotherapeutic target or to improve the efficacy of chemotherapy for PDAC.
Authors
- Nengwen Ke (ORCID: https://orcid.org/0000-0002-7135-2244)
- Zerong Xie (ORCID: https://orcid.org/0000-0002-7679-5183)
- Yu Mou (ORCID: https://orcid.org/0000-0002-4528-4487)
- Chen Chen (ORCID: https://orcid.org/0000-0003-2104-534X)
- Ruiman Geng
- Ziyao Wang
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Chengdu Women's and Children's Central Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70110
- Citations
- 3
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.72